Compare Kingsoft Cloud Holdings Limited (KC) vs 10X Genomics Inc (TXG) Price & Performance

Kingsoft Cloud (KC) trades at $9.26, up 0.33% with bearish technical indicators but strong analyst support. The company shows improving fundamentals with Q2 2026 revenue growth of 30.8% year-over-year and three consecutive earnings beats. Despite negative net margins, gross margins improved significantly to 15.05% as AI cloud services drive growth. Cash flow from operations reached $3.8 billion in 2025, though 2026 projections show negative net cash flow.

KC presents a compelling turnaround story with AI-driven growth potential, trading at attractive valuation multiples (P/S: 1.58, EV/EBITDA: 2,203). However, persistent losses and negative cash flow projections for 2026 pose significant execution risks. The 70% analyst buy rating and 60% upside potential must be weighed against the bearish technical picture and competitive cloud market dynamics.

TXG trades at $80.65, up 5.98% on the day, showing strong recent momentum despite a bearish technical signal. The company reported revenue of $642.82M for 2025 with a gross margin of 70.03%, but remains unprofitable with a net loss of $43.54M. Recent news highlights the launch of the Atera spatial biology platform and a patent victory, signaling innovation and competitive strength. Analyst consensus is mixed with a $74.30 price target below the current price, indicating caution on valuation.

The outlook for TXG hinges on commercial execution of new products like Atera to drive revenue growth and a path to profitability. Investment opportunity lies in its leading technology platform and expanding market demand in genomics. Key risks include persistent losses, high valuation multiples, and competitive pressures in the life sciences tools sector. The stock's recent rally faces a test near technical resistance at $81.